Wednesday, August 10News That Matters
Shadow

Tag: carcinogen

Blood pressure drug recall expands over third possible carcinogen

Blood pressure drug recall expands over third possible carcinogen

Health
March 2 (UPI) -- Drug companies expanded a recall of Losartan lots after detecting a third potentially cancer-causing impurity in blood pressure medication. Camber Pharmaceuticals voluntarily recalled an additional 87 lots of Losartan potassium drugs used to treat high blood pressure and congestive heart failure Thursday. The detection of trace amounts of a new potential human carcinogen, known as N-Nitroso-N-methyl-4-aminobutyric acid or NMBA, prompted the recall. On Friday, Torrent Pharmaceuticals voluntarily recalled 60 lots of Losartan potassium tablets and 54 lots of Losartan potassium/hydrochlorothiazide, similarly over the detection of trace amounts of NMBA. The recalled tablets from both companies were made by Hetero Labs in India. Each company noted it has not received any repor...
FDA: Irbesartan lots recalled over likely carcinogen

FDA: Irbesartan lots recalled over likely carcinogen

Health
Jan. 19 (UPI) -- A drug company has recalled more irbesartan blood pressure medication after discovering a potential human carcinogen. Prinston Pharmaceutical, doing business as Solco Healthcare, has voluntarily recalled of eight more lots of irbesartan blood pressure medication after detecting trace amounts of impurity in an active pharmaceutical ingredient, the Food and Drug Administration announced Friday. The ingredient in question contains N-nitrosodiethylamine (NDEA), "a substance that occurs nationally in certain foods, drinking water, air pollution, and industrial processes" and has been classified by the International Agency for Research on Cancer as a probable human carcinogen. NDEA was manufactured by a factory in China called Zhejiang Huahai Pharmaceuticals, which has been lin...